Ignite Creation Date:
2025-12-24 @ 10:04 PM
Ignite Modification Date:
2025-12-30 @ 1:24 PM
Study NCT ID:
NCT04514835
Status:
UNKNOWN
Last Update Posted:
2021-08-25
First Post:
2020-08-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-01-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-01-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-08-05
First Submit QC Date:
None
Study First Post Date:
2020-08-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-08-19
Last Update Post Date:
2021-08-25
Last Update Post Date Type:
ACTUAL